28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Outcomes of interest were duration of delirium, health-related quality of life, delirium severity, cognitive function, mortality in the ICU, ICU length of stay, hospital length of stay and adverse events. 5 key findings →
Design: meta-analysis Participants: 491 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There is increasing evidence to suggest that physical activity has a protective effect on brain functioning in older people. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The beneficial effects of a ketogenic diet (KD) on neurodegenerative conditions such as mild cognitive impairment (MCI) and Alzheimer disease (AD) are increasingly acknowledged, with potential implications for the general population as well. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sixty-six studies met inclusion criteria for the relationship between physical activity and functional independence, and 34 were included with a cognitive function outcome. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Quantitative imaging of cerebral blood flow and metabolism by positron emission tomography can differentiate between vascular dementia and degenerative dementia and show the interaction between vascular and metabolic changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Nutrition is an important lifestyle factor that can modify the risk of future cognitive impairment and dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nearly half of all adults older than 60 years of age report sleep disturbance, as characterised either by reports of insomnia complaints with daytime consequences, dissatisfaction with sleep quality or quantity, or the diagnosis of insomnia disorder. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On the eve of the 2012 summer Olympic Games, the first Lancet Series on physical activity established that physical inactivity was a global pandemic, and global public health action was urgently needed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
When compared with the Low MedDiet group, the High MedDiet group was associated with better L&M performance and larger dentate gyri. 5 key findings →
Design: cross-sectional Participants: 82 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings in CPAP+ participants suggest that CPAP treatment of SDB may delay progression of cognitive impairment. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this large series of PSG-confirmed and probable RBD cases that underwent autopsy, the strong association of RBD with the synucleinopathies was further substantiated and a wider spectrum of disorders which can underlie RBD now are more apparent. 2 key findings →
Participants: 147 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These cases illustrate that the alpha-synuclein pathogenic process may start decades before the first symptoms of PD, DLB, or MSA. 1 key finding →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alternatively, lesser engagement in social activities may be a marker of impending cognitive decline in MCI. 1 key finding →
Design: cohort study Participants: 78 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Evidence is insufficient to support the use of pharmaceutical agents or dietary supplements to prevent cognitive decline or Alzheimer’s disease. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cognitive functions and self-reported drinking habits were assessed at 2-year intervals over an average of 7 years of follow-up. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study tested the hypotheses that late-midlife obstructive sleep apnea (OSA) and short and long sleep duration are associated with dementia over 15 years of follow-up. 4 key findings →
Participants: 1,667 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Whether or not there is targeted pharmacotherapy for dementia, an active and healthy lifestyle that includes physical activity (PA) may be a better option than medication for preventing dementia. 4 key findings →
Participants: 484,169 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Here we show that the associations of 57 metabolites with dementia risk varied by APOE4 genotype or other AD/ADRD risk variants. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The introduction of incretin mimetics (IMs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as liraglutide and semaglutide, as well as dual GLP-1/glucose-dependent insulinotropic polypeptide receptor co-agonists (GLP-1/GIP RAs) like tirzepatide, has revolutionized obesity treatment. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The human metabolome reflects complex metabolic states affected by genetic and environmental factors. 5 key findings →
Participants: 23,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In total, 41 participants consented (n=10, 24% participants with Alzheimer disease; n=11, 27% participants with Lewy body disease; and n=20, 49% controls). 5 key findings →
Design: longitudinal study Participants: 41 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 110 participants (mean [SD] age, 67.9 [4.6] years; 68 female [61.8%]) were randomized to the experimental group (n = 55) and the sham group (n = 55) and included in the intention-to-treat analysis. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study examined the combined effects of StrongerMemory program (brain exercises involving reading, writing, and math) and weekly social engagement on cognitive, behavioral, and emotional outcomes in older adults with subjective cognitive decline (SCD). 4 key findings →
Design: randomized controlled trial Participants: 50 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The Mediterranean Dietary (MedDiet) Pattern has been linked to many beneficial health effects. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Evidence from a limited number of randomised controlled intervention trials (RCTs) have shown that a Mediterranean dietary pattern may reduce the risk of cognitive decline and enhance cognitive function among healthy older adults. 3 key findings →
Participants: 137 Evidence: high
Full summary, score breakdown and related studies → Original source
10 of the 1,888 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →